论文部分内容阅读
目的:评价孟鲁司特钠与氯雷他定联用治疗小儿咳嗽变异性哮喘患儿的临床疗效。方法:选取2011年5月—2014年5月期间收治的小儿咳嗽变异性哮喘患者76例,将其按照治疗方法分为对照组和观察组,每组38例;对照组患儿给予常规方法治疗,观察组患儿给予孟鲁司特钠与氯雷他定联用治疗,治疗结束后比较两组患儿的临床症状改善情况及总有效率。结果:观察组患者治疗后的总有效率为94.74%显著高于对照组为76.32%(P<0.05);观察组患者治疗后咳嗽、肺部哮鸣音消失时间和哮喘消失时间分别为(6.54±0.98)d、(3.61±0.52)d和(3.61±1.39)d低于对照组分别为(12.36±1.78)d、(9.14±1.78)d和(7.96±1.62)d(P<0.05);观察组患儿不良反应的发生率为2.63%显著低于对照组为21.5%(P<0.05)。结论:孟鲁司特钠与氯雷他定联用治疗小儿咳嗽变异性哮喘患儿的临床疗效优于常规方法治疗,其病情恢复情况较为理想,总有效率较高,不良反应的发生率较低。
Objective: To evaluate the clinical efficacy of combination of montelukast sodium and loratadine in children with cough variant asthma. Methods: 76 children with cough variant asthma admitted from May 2011 to May 2014 were selected and divided into control group and observation group according to the method of treatment, with 38 cases in each group. The control group received routine treatment , Montelukast sodium and loratadine were given to the observation group. After the treatment, the improvement of the clinical symptoms and the total effective rate of the two groups were compared. Results: The total effective rate of the observation group after treatment was 94.74%, which was significantly higher than that of the control group (76.32%, P <0.05). The cough, disappearance of lung wheeze and disappearance time of asthma in the observation group were (6.54 ± 0.98) d, (3.61 ± 0.52) d and (3.61 ± 1.39) d, respectively, which were significantly lower than those in the control group (12.36 ± 1.78 and 9.14 ± 1.78 and 7.96 ± 1.62, respectively, P <0.05) The incidence of adverse reactions in observation group was significantly lower than that in control group (2.63% vs 21.5%, P <0.05). Conclusion: The combination of montelukast sodium and loratadine in children with cough variant asthma is superior to the conventional treatment of clinical efficacy, the recovery of the condition is more ideal, the total effective rate is higher, the incidence of adverse reactions than low.